For Patients With Partial-Onset (Focal) Seizures

PATIENTS FIRST,
BRIVIACT FIRST

APPROVED FOR PATIENTS
AS YOUNG AS 1 MONTH OF AGE1

Veronica is an actual patient living with focal seizures.

BRIVIACT® (brivaracetam) CV is indicated for the treatment of partial-onset seizures in patients 1 month of age and older.

Click Here to View Important Safety Information

 

BRIVIACT is approved for pediatric patients 1 month of age and older.
Available in oral solution, tablets, and IV* formulations.1

*For use when oral administration is temporarily not feasible.1

Copay/Savings

Multiple Resources to Provide
Savings and Support for
BRIVIACT Patients

BRIVIACT® (brivaracetam) CV Patients May Pay as Little as $10 per Month with the Patient Savings Card

BRIVIACT Patient Savings Program

Eligible Patients Pay As Little As $10 per 30-Day Supply of BRIVIACT With the BRIVIACT Patient Savings Program*

Ask your representative for details about the program.

    • *Patients are responsible for a minimum of $10 out-of-pocket expense per 30-day supply. This card will be applied to any remaining out-of-pocket expense up to a maximum of $1300. Most patients who have commercial prescription insurance are eligible. If you have any questions regarding your eligibility or benefits or if you wish to discontinue your participation, call the BRIVIACT Savings Program at 1-888-786-5879 (8:30 AM – 5:30 PM EST, Monday-Friday and 8:30 AM – 2:30 PM EST, Saturday). This savings card is not valid for use by patients who are covered by any federally funded or state-funded healthcare program (including, but not limited to, Medicare [Part D and Medigap] and those who are Medicare-eligible and enrolled in an employer-sponsored health plan for retirees, Medicaid, any state pharmaceutical assistance program, TRICARE, VA, or DoD), or for cash-paying patients. Offer good only in the U.S., including Puerto Rico. This card is good for use only with a valid BRIVIACT prescription consistent with the approved FDA labeling at the time the prescription is filled by the pharmacist and dispensed to the patient. The maximum annual benefit amount is $1300 per calendar year. Void where prohibited by law, taxed, or restricted. This offer cannot be combined with any other promotional offer. UCB, Inc. reserves the right to rescind, revoke, or amend this offer without notice at any time. No cash value. Not eligible for sale, purchase, trade, or counterfeit.

    UCB is committed to making BRIVIACT accessible for the majority of eligible patients across the US†

    9 out of 10
    commercial patients have formulary access to BRIVIACT2

    Approximately 2/3 of patients across Commercial, Medicare, and Medicaid could have access to BRIVIACT first. This means they should not have to try and fail other anti-seizure medications, including generics, for their insurance to cover BRIVIACT.3†

    • †Formularies can change and many health plans offer more than one formulary. Please check directly with the health plan to confirm coverage for individual patients.

Assistance

Financial assistance may be available for BRIVIACT® patients

The BRIVIACT Patient Assistance Program may be able to help if your patients do not have health insurance or if they are a Medicare Part D recipient and cannot afford BRIVIACT.

To learn more about the BRIVIACT Patient Assistance Program or to find out if your patient might be eligible for assistance, please contact ucbCARES® at 1-844-599-CARE (2273) or ucbCARES@ucb.com, or click below to get started.

Program instructions and application form

A FREE 2-Week Trial of BRIVIACT for new patients

New patients may be eligible for a FREE Trial Voucher with a 14-day prescription.

Contact your representative to receive a patient voucher for a 14-day supply of BRIVIACT.

Or call ucbCARES at 1-844-599-CARE (2273) or email ucbCARES@ucb.com.

Important Safety Information

WARNINGS AND PRECAUTIONS

  • Suicidal Behavior and Ideation: Antiepileptic drugs, including BRIVIACT, increase the risk of suicidal behavior and ideation. Monitor patients taking BRIVIACT for the emergence or worsening of depression; unusual changes in mood or behavior; or suicidal thoughts, behavior, or self-harm. Advise patients, their caregivers, and/or families to be alert for these behavioral changes and report them immediately to a healthcare provider.
  • Neurological Adverse Reactions: BRIVIACT causes somnolence, fatigue, dizziness, and disturbance in coordination. Somnolence and fatigue-related adverse reactions were reported in 25% of adult patients taking at least 50 mg per day of BRIVIACT compared to 14% of adult patients taking placebo. Dizziness and disturbance in gait and coordination were reported in 16% of adult patients taking at least 50 mg per day of BRIVIACT compared to 10% of adult patients taking placebo. The risk is greatest early in treatment but can occur at any time. Monitor patients for these signs and symptoms and advise them not to drive or operate machinery until they have gained sufficient experience on BRIVIACT.
  • Psychiatric Adverse Reactions: BRIVIACT causes psychiatric adverse reactions, including non-psychotic and psychotic symptoms. These events were reported in approximately 13% of adult patients taking at least 50 mg per day of BRIVIACT compared to 8% of adult patients taking placebo. A total of 1.7% of adult patients taking BRIVIACT discontinued treatment due to psychiatric reactions compared to 1.3% of patients taking placebo. Psychiatric adverse reactions were also observed in open-label pediatric trials and were generally similar to those observed in adults. Advise patients to report these symptoms immediately to a healthcare provider.
  • Hypersensitivity: BRIVIACT can cause hypersensitivity reactions. Bronchospasm and angioedema have been reported. Discontinue BRIVIACT if a patient develops a hypersensitivity reaction after treatment. BRIVIACT is contraindicated in patients with a prior hypersensitivity reaction to brivaracetam or any of the inactive ingredients.
  • Withdrawal of Antiepileptic Drugs: As with all antiepileptic drugs, BRIVIACT should generally be withdrawn gradually because of the risk of increased seizure frequency and status epilepticus.

DOSING CONSIDERATIONS

  • Dose adjustments are recommended for patients with all stages of hepatic impairment.
  • When BRIVIACT is co-administered with rifampin, an increase in the BRIVIACT dose is recommended.

ADVERSE REACTIONS

In adult adjunctive therapy placebo-controlled clinical trials, the most common adverse reactions (at least 5% for BRIVIACT and at least 2% more frequently than placebo) were somnolence and sedation, dizziness, fatigue, and nausea and vomiting symptoms. Adverse reactions reported in clinical studies of pediatric patients were generally similar to those in adult patients. Adverse reactions with BRIVIACT injection in adult and pediatric patients were generally similar to those observed with BRIVIACT tablets. Other adverse events that occurred in adult patients who received BRIVIACT injection included dysgeusia, euphoric mood, feeling drunk, and infusion site pain.  

BRIVIACT is a Schedule V controlled substance.

Please see full Prescribing Information

References

  1. BRIVIACT® (brivaracetam): US prescribing information. Smyrna, GA: UCB, Inc.
  2. Data on file. UCB, Inc.
  3. Managed Markets Insight & Technology, LLC, database as of August 2021.